ATE344030T1 - 4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität - Google Patents

4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität

Info

Publication number
ATE344030T1
ATE344030T1 AT03775181T AT03775181T ATE344030T1 AT E344030 T1 ATE344030 T1 AT E344030T1 AT 03775181 T AT03775181 T AT 03775181T AT 03775181 T AT03775181 T AT 03775181T AT E344030 T1 ATE344030 T1 AT E344030T1
Authority
AT
Austria
Prior art keywords
piperazinylbenzenesulfonyl
indoles
receptor affinity
affinity
receptor
Prior art date
Application number
AT03775181T
Other languages
English (en)
Inventor
Robin Douglas Clark
Ralph New Harris Iii
David Bruce Repke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE344030T1 publication Critical patent/ATE344030T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT03775181T 2002-10-18 2003-10-13 4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität ATE344030T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41936902P 2002-10-18 2002-10-18

Publications (1)

Publication Number Publication Date
ATE344030T1 true ATE344030T1 (de) 2006-11-15

Family

ID=32108067

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03775181T ATE344030T1 (de) 2002-10-18 2003-10-13 4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität

Country Status (21)

Country Link
US (1) US7022708B2 (de)
EP (1) EP1556037B1 (de)
JP (1) JP2006505559A (de)
KR (1) KR20050073560A (de)
CN (1) CN1309384C (de)
AR (1) AR041635A1 (de)
AT (1) ATE344030T1 (de)
AU (1) AU2003283265B2 (de)
BR (1) BR0315317A (de)
CA (1) CA2501172A1 (de)
DE (1) DE60309498T2 (de)
ES (1) ES2274285T3 (de)
GT (1) GT200300226A (de)
MX (1) MXPA05004128A (de)
PA (1) PA8586401A1 (de)
PE (1) PE20040691A1 (de)
PL (1) PL376479A1 (de)
RU (1) RU2324693C2 (de)
TW (1) TW200418456A (de)
UY (1) UY28026A1 (de)
WO (1) WO2004035047A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098857A1 (en) * 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag New indole derivatives with 5-ht6 receptor affinity
DK1497266T3 (da) 2002-03-27 2008-10-06 Glaxo Group Ltd Quinolinderivater og deres anvendelse som 5HT6-ligander
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
CN1980672B (zh) 2004-03-15 2011-05-04 Ptc医疗公司 用于抑制血管生成的咔啉衍生物
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (de) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Verfahren zur behandlung von hepatitis c
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
AU2005275182A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating Hepatitis C
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
CN101031338B (zh) 2004-09-30 2013-01-02 弗·哈夫曼-拉罗切有限公司 治疗认知障碍的组合物和方法
US7998981B2 (en) * 2005-08-12 2011-08-16 Suven Life Sciences Limited Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands
BRPI0614343A2 (pt) * 2005-08-15 2011-03-22 Wyeth Corp derivados de 3-sulfonilindazol substituìdo como ligantes de 5-hidroxitriptamina-6
US7923566B2 (en) 2005-08-16 2011-04-12 Suven Life Sciences Limited Alternative process for the preparation of losartan
KR20080114688A (ko) * 2006-01-13 2008-12-31 와이어쓰 5-히드록시트립타민 수용체에 대한 리간드로서의 술포닐 치환된 1h-인돌
ES2358549T3 (es) 2006-11-09 2011-05-11 F. Hoffmann-La Roche Ag Arilsulfonil, pirrolidinas como inhibidores de 5-ht6.
EP2118062A1 (de) 2007-01-10 2009-11-18 F. Hoffmann-Roche AG Sulfonamidderivate als chymase-hemmer
AU2008315309B2 (en) * 2007-10-26 2011-06-09 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-HT6 ligands
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010032257A1 (en) * 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
WO2011044134A1 (en) * 2009-10-05 2011-04-14 Albany Molecular Research, Inc. Epiminocycloalkyl(b)indole derivatives as serotonin sub-type 6 (5-ht6) modulators and uses thereof
AU2012207335A1 (en) 2011-01-19 2013-07-25 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
JP6203820B2 (ja) 2012-04-16 2017-09-27 ケース ウエスタン リザーブ ユニバーシティ 15−pgdh活性を調節する組成物および方法
CN104276993B (zh) * 2013-07-12 2019-03-15 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
US9789116B2 (en) 2013-10-15 2017-10-17 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CN104557726B (zh) * 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
JP6454346B2 (ja) * 2013-12-20 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. 芳香族複素環式化合物及び医薬におけるその応用
SG11201610407QA (en) 2014-07-08 2017-01-27 Sunshine Lake Pharma Co Ltd Aromatic heterocyclic derivatives and pharmaceutical applications thereof
KR20180022792A (ko) 2015-06-12 2018-03-06 엑소반트 사이언시즈 게엠베하 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
JP2020502070A (ja) 2016-11-30 2020-01-23 ケース ウエスタン リザーブ ユニバーシティ 15−pgdh阻害剤とコルチコステロイドおよび/またはtnf阻害剤との組み合わせならびにその使用
EP3576737A4 (de) 2017-02-06 2021-04-21 Case Western Reserve University Zusammensetzungen und verfahren zur modulation der aktivität von kurzkettiger dehydrogenase
CN109232362B (zh) * 2017-07-10 2022-12-27 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
WO2023078252A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9116732D0 (en) 1991-08-02 1991-09-18 Fujisawa Pharmaceutical Co Indole derivatives
FR2729144A1 (fr) 1995-01-06 1996-07-12 Smithkline Beecham Lab Nouvelles diamines, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu' agents anti-arythmiques
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
HUP0003073A3 (en) 1997-07-11 2002-10-28 Smithkline Beecham Plc Benzenesulfonamide derivatives, process for producing them and their use as medicines
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
WO2000058304A1 (fr) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Derives sulfonamides heterocycliques
DK1259485T3 (da) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
WO2002032863A1 (en) * 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
ATE337780T1 (de) * 2000-11-24 2006-09-15 Smithkline Beecham Plc Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5-ht6受体亲和力的4-哌嗪基吲哚衍生物
CN1293053C (zh) * 2002-06-05 2007-01-03 弗·哈夫曼-拉罗切有限公司 作为5-ht6-受体调节剂用于治疗cns-病症的1-磺酰基-4-氨基烷氧基吲哚衍生物
JP4754821B2 (ja) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物
MXPA05002836A (es) * 2002-09-17 2005-05-27 Hoffmann La Roche Indoles 2,4-sustituidos y su uso como moduladores 5-ht6.

Also Published As

Publication number Publication date
DE60309498D1 (de) 2006-12-14
WO2004035047A1 (en) 2004-04-29
GT200300226A (es) 2004-10-18
RU2324693C2 (ru) 2008-05-20
AR041635A1 (es) 2005-05-26
MXPA05004128A (es) 2005-06-22
US20040087593A1 (en) 2004-05-06
BR0315317A (pt) 2005-09-06
KR20050073560A (ko) 2005-07-14
AU2003283265B2 (en) 2009-03-05
CN1309384C (zh) 2007-04-11
RU2005115115A (ru) 2006-01-20
AU2003283265A1 (en) 2004-05-04
EP1556037A1 (de) 2005-07-27
TW200418456A (en) 2004-10-01
PL376479A1 (en) 2005-12-27
DE60309498T2 (de) 2007-08-30
CA2501172A1 (en) 2004-08-29
ES2274285T3 (es) 2007-05-16
PE20040691A1 (es) 2004-10-16
CN1705480A (zh) 2005-12-07
US7022708B2 (en) 2006-04-04
JP2006505559A (ja) 2006-02-16
UY28026A1 (es) 2004-04-30
PA8586401A1 (es) 2005-08-04
EP1556037B1 (de) 2006-11-02

Similar Documents

Publication Publication Date Title
ATE344030T1 (de) 4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität
ATE353318T1 (de) Neue indolderivate mit affinität zum 5-ht6- rezeptor
ATE501118T1 (de) Substituierte indole
ATE331707T1 (de) 4 piperazinylindolderivate mit affinität zum 5- ht6-rezeptor
DE60332125D1 (de) Indole mit antidiabetischer wirkung
ATE392206T1 (de) Indolderivate als beta-2 agonisten
DE60328401D1 (de) IP Redundanz mit verbesserter Übergabenachrichtigung
ATE340792T1 (de) Substituierte indole als alpha-1 agonisten
ATE465995T1 (de) N-'(1,5-diphenyl-1h-pyrazol-3- yl)sulfonamidderivate mit affinität zum cb1- rezeptor
AU2003244480A1 (en) Sulphonyl compounds with 5 -ht6 receptor affinity
ATE544762T1 (de) Calcium rezeptor modulatoren
FI20060188A (fi) Modifioidut IL-4-muteiinin reseptorin antagonistit
DE50306919D1 (de) Gelenkaussenteil mit Abstützscheibe
DK1587788T3 (da) 2,7-substituerede indoler og anvendelsen deraf som 5-HT6-modulatorer
NO20043396L (no) Kortikotropinfrigjorende faktorreseptor 2-agonister
DE60306911D1 (de) Spaltoven mit gleichmässiger heizung
DE60319184D1 (de) Dreirad mit Schwingmechanismus
DE60321752D1 (de) Halterung mit rotationssymmetrischen Taschen
DE60319512D1 (de) Drehgelenk
DE602004005628D1 (de) Halterung mit mehreren Brücken
DE60325794D1 (de) Tonerzusammensetzungen mit glanzsteuernden Eigenschaften
NO20021944L (no) Slepebåt
DE60300799D1 (de) Fahrzeug mit Sattel
DE50310181D1 (de) Drosselklappeneinheit
FR2847624B1 (fr) Joint spherique

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1556037

Country of ref document: EP

REN Ceased due to non-payment of the annual fee